Beaverton vaccine developer nabs $3M grant to start clinical trial
Beaverton-based Najit Technologies Inc. received a $3.1 million grant to test a yellow fever vaccine in humans for the first time.
The award from the National Institutes of Health will allow the OHSU spinout to get its HydroVax platform in a phase 1 clinical trial to study how participants’ immune systems respond.
The current yellow fever vaccine has been used since the 1930s. While it works for the majority of people who take it, infants and the elderly can become ill from the vaccine.
“We…
Source: bizjournals.com Health Care:Pharmaceuticals headlines - Category: Pharmaceuticals Authors: Elizabeth Hayes Source Type: news
More News: Clinical Trials | Grants | Health Management | National Institutes of Health (NIH) | Pharmaceuticals | Study | Vaccines | Yellow Fever | Yellow Fever Vaccination